Industry Update - Cement industry forecast for Q1FY2009

Key points:
  • It looks that severe cost pressures will continue to impact profitability of companies in the Cement sector. Overall, select cement companies have registered a 6% growth in the volumes in Q1FY2009. Companies like Shree Cement, Madras Cements and Orient Paper and Industries have reported an impressive volume growth of around 26%, 12% and 10% respectively. This was mainly due capacity enhancements carried out by them.
  • In terms of realisation, India Cement is expected to show a strong growth of 16.3% in its realisation due to a change in its market mix. Apart from this, the average realisation for Orient Paper and Industries is expected to increase by 13.2%, as the average realisation in the corresponding quarter of the last year was depressed due to clinker sales.
  • Despite this, the cement industry as such looks quite promising. I estimate an average growth of 11.6% in the revenues and a almost 17% decline in the earnings for the select companies.

Industry Update - Pharma industry forecast for Q1FY2009

Key points:

  • Companies which I am considering here would report almost a 30.9% increase in their revenues for Q1FY2009. Major driver for this mammoth growth would be a steady growth in the domestic market, the new product launches in the regulated markets, strong growth in the contract research and manufacturing services businesses, and the consolidation of the acquisitions made in the previous year. As exports command over 50% share of the pharma industry's revenues, the weaker rupee would also aid the top line.
  • The operating profit margin of companies (that are covered here) is expected to expand by 330 basis points, largely driven by exclusivity revenues (Sun Pharmaceuticals), savings arising out of the de-merger of R & D units (Piramal Healthcare) and the effect of operating leverage for companies with a strong top line growth (Lupin and Ranbaxy). On the other hand, rising input, power and fuel costs would negatively affect the margins of companies like Orchid Chemicals and Surya Pharmaceuticals. Wockhardt and Opto Circuits may reel under margin pressure on account of the consolidation of low-margin acquisitions.
  • Despite a strong top line growth and a robust operating performance, the reported net profit of companies would grow just by 1.6%. This would be on account of the mark-to-market losses recorded by companies like Ranbaxy Laboratories, Orchid, Wockhardt and IPCA Laboratories (because they have outstanding forex liabilities). Higher interest and depreciation costs (due to acquisitions) would also affect the reported profits in the case of Wockhardt, Cadila and Opto. On excluding the forex impact, the adjusted net profits of these companies might grow by 50.5%.
  • My personal top picks include Sun Pharma (which surprised positively with higher than expected exclusivity revenues), and Lupin (which is expected to deliver strong top line and bottom line growth). On the other hand, companies like Ranbaxy, Wockhardt and Orchid could surprise negatively due to higher than anticipated forex losses.
  • The key risk to the above estimates is companies reporting mark-to-market losses on hedging instruments or on foreign currency derivatives. I believe Ranbaxy & Wockhardt would have outstanding foreign currency hedges, on which they could incur certain losses.

Stock Idea - Cadila Healthcare

Recommendation: Buy

CMP = Rs 314 (at the time of this recommendation)

Price target: Rs 372

Key points:

  • Cadila Healthcare (Cadila) has decided to hive-off its consumer product business and merge the same with its listed subsidiary, Carnation Nutra Analogue. In consideration, Carnation Nutra will allot to shareholders of Cadila four fully-paid-up equity shares of Rs 10 each for 15 equity shares of Rs 5 each held in Cadila. Consequently, Cadila's stake in Carnation Nutra would increase from 61.56% currently to 70.2% post the restructuring.
  • Cadila would also amalgamate Zydus Hospital and Medical Research Private Ltd with itself by canceling the existing nine crore shares held by Zydus Hospital in Cadila and issuing 10.08 crore fresh equity shares to Zydus Hospital. The move would result in equity dilution of 8.7% in Cadila and add no value for the minority shareholders. The restructuring is intended to consolidate the group's consumer product business under one entity and aims to unlock value in its consumer product business. 
  • In consideration for the consumer product business, Cadila shareholders would get additional shares of Carnation Nutra (4:15 – 4 shares of Carnation Nutra for every 15 shares of Cadila). I would value Carnation Nutra stock at Rs 87 per share.
  • I maintain Buy call with a price target of Rs 372.

Entrecard brings you a lot of cash - literally!

IT'S RAINING CASH... I am serious. Entrecard is giving out lots of prizes in cash / kind in this arguably the biggest virtual SALE!! Here is the list to soothe your eyes:

I personally want to win the Fantasy Baseball prize... because 10,000 credits is huge! I can do many things with it...

Prizes in Cash ( ≡ Entrecard credits)

Fantasy Baseball - 10,000ec — You can trade in 10,000ec!!
Q3-n - 5000ec — Q3-n is selling their 1950s dinette furniture to finance this contest.
Øblog - 4000ec — Wow! 4000ec is going for like $30 on the Entrecard market.
Evil Woobie - 3000ec…
Turnip of Power - 1001ec…
Celebrity Pictures - 1000ec — Credits were acquired through legal means.
Evil Entrecard Kid! - 1000ec — Entrecard trivia: Evil Woobie and Evil Entrecard Kid are not related. Yet.
Modern Glam - 1000ec…
Dot Com Mogul - 1000ec — With this 1000ec, you might be able to buy back Q3-n's dinette furniture.
Blabberwocky - 1000ec — It's a play on Jabberwocky.
Looking For Scoop - 1000ec…
Eyespi20.com - 1000ec — And she'll teach you how she does that weird signature thing.
Travelin' Show - 1000ec…
The Hypnotist - 1000ec — She will put you under a spell. Recognize!
Diet Pulpit - 1000ec — You can buy a lot of imaginary rice cakes with 1000ec.
J
The Realtor - 500ec — You want insight. Listen to her write.
Romelo - 500ec — Romelo, Romelo, wherefore art thou 500ec?
WebATBP.com - 500ec…
Inspire Emotion - 500ec — Almost pay for your favorite 512ec ad!
Sue Doe-Nim - 500ec — She'll probably give you the credits then mock you for wanting them.
Thailand Land of Smiles - 500ec — Actually, that's 500 smiles.
FitnessLifeClub - 500ec…
Lisa Cooking - 500ec — Surprise the whole family with 500 Entrecard credits.
JunkieYard Dot Com - 500ec…
Movie Reviews - 500ec…

Prizes in kind

Aerten Art - She's donating a painting. Seriously. Go look at her site and tell me you wouldn't want a painting.
ImpNERD - 125×125 ad for a month — Let's see, ImpNERD usually sells advertising for 256ec/day. You get this for a month.
PoemsofQuotes - A cheesy poem about the winner's topic!!
Eyespi20.com - A custom made 125×125 card.
Diet Pulpit - One week ad spot right below the banner and a personal greeting from Lady Rose saying, "Congratulations!"…
JunkieYard Dot Com - Three blogroll links.
The Hypnotist - A Hypnotic Audio…

HOW to win??? It's very simple; check out Entrecard rules & guidelines to win this contest!

Stock Idea - ICICI Bank

Recommendation: Buy

CMP = Rs 601 (at the time of this recommendation)

Price target: Rs 1,204

Key points:

  • Margins and not volumes is what ICICI Bank seems to be focusing on now. The current account and savings account growth will be the key driver for margin expansion going forward. A deceleration in the advances book growth and a near 100% growth in the incremental growth proves the point.
  • With seasoning of credit portfolio, the bank has seen an up tick in delinquencies. Rapid growth in unsecured lending (CAGR of 82%) as compared to total advances (CAGR of 24%) over the past three years is likely to put further strain on the asset quality. The rising interest rate scenario may further worsen things for the bank.
  • ICICI Bank's contingent liability increased by 105% in FY2008. 90% of this constitutes exposure in currency & interest rate swaps and other derivative instruments. In view of the Reserve Bank of India's latest provisioning guidelines related to these instruments, the bank may have to make additional provisions. Unfavorable market conditions raises concern over the bank's higher exposure to sensitive sectors like real estate and capital markets. The management, however, believes that the road ahead will be challenging considering the worsening global and domestic economic scenario. Despite this, the management is bullish on India's long-term growth prospects and foresees robust growth outlook for the Indian financial sector. 
  • At the current market price of Rs 601, the stock trades at 13.7x 2009E earnings per share.
  • I maintain a strong Buy recommendation on the stock with a price target of Rs 1,204.

Stock Idea - Navneet Publications (India)

Recommendation: Buy

CMP = Rs 66.5 (at the time of this recommendation)

Price target: Rs 80

Key points:

  • The net sales of Navneet Publications Ltd (NPL) for Q4FY08 grew by a robust 29.5% yoy to Rs 59.1 crore. The sales growth was on account of hefty growth in publication and stationery businesses. The publication business witnessed a robust growth of 28.5% yoy to Rs 21.8 crore. The stationery business achieved a healthy growth of 33.8% yoy to Rs 38.0 crore, mainly on account of good domestic demand and introduction of non-paper stationery products.
  • The operating profit margin declined by 102 basis points to 9.0%, mainly on account of a higher other expenditure. An additional promotional expenditure of Rs 1.5 crore towards the stationery business led to a steep hike of 47% in the other expenditure to Rs 15.9 crore. The other income for Q4FY08 stood at Rs 1.0 crore as compared to Rs 0.5 crore during Q4FY07. A higher other income coupled with a lower incidence of tax led to a 57.1% growth in the reported net profit to Rs 2.1 crore.
  • Going forward the publication segment, one of the major revenue contributors for NPL, will achieve a moderate growth, as in FY2009 revision of syllabus is due only for a few standards in the states of Gujarat and Maharashtra. However, the growth in near future will be driven by some of the new initiatives undertaken by the company such as introduction of non-paper stationery products, foray into Urdu publication and e-learning business. 
  • At the current market price of Rs 66.5, the stock is trading at 8.8X its 2010 estimated EPS and at an enterprise value /earnings before interest, depreciation, tax and amortisation of 5.7X.
  • I maintain a strong Buy recommendation with a price target of Rs 80 over next 6 months.

Monetary squeeze & high Inflation expected to continue...

The Reserve Bank of India (RBI) stepped up its efforts to tame inflation by increasing both the repo rate and the Cash Reserve Ratio (CRR) rate by 50 basis points each (100 basis points = 1 percentage point). This latest move reflects the reversal in interest rate expectations in 2008. With domestic inflation under control and a slowdown in industrial production, markets were expecting monetary easing at the start of the year. However, a sharp rise in headline inflation numbers changed the interest rate environment dramatically.

The economy had witnessed a period of sustained high growth rate for the past few years and relatively lower inflation, helped by pre-emptive actions taken by RBI. It had withstood the rise in oil and commodity prices relatively well, helped by strong growth and the absence of a full passthrough of global energy prices. However, sustained domestic demand and rising imported inflation have led to a sharp rise in headline inflation numbers since March, leading to a slew of fiscal and monetary measures. This culminated in the multiyear high inflation numbers released two weeks ago, and RBI’s 50 basis-point hike in CRR and repo rates last week. Thus yields have moved up sharply across the curve.

On the other hand, strong capital outflows and concerns about the widening trade deficit have resulted in the rupee losing ground against major currencies. Despite the US dollar weakening in 2008, the rupee has weakened against the greenback. On the fiscal front, off-balance sheet items such as oil and fertiliser subsidies, the farm loan waiver and possible wage hikes due to Sixth Pay Commission recommendations, are raising concerns. Despite recent strong trends in advance tax payments, there are worries about possible revenue pressures due to an expected economic slowdown. In recent weeks,we have seen an uptick in nonfood credit growth—26.2% as of June 6.

While India’s external position remains strong, helped by large foreign exchange reserves and a relatively low external debt-to-GDP ratio, investors are worried about the impact of the increasing value of oil imports and FII outflows on the current account deficit. The RBI has clearly indicated that aggregate demand pressures have been on the higher side, despite monetary tightening, and seems focused on alleviating inflationary pressure. It has indicated that key economic drivers—investment and consumption—are strong, contributing to increased demand. In such a scenario, global oil prices and inflationary pressures are likely to determine domestic monetary policy.

In the near term, monetary policy is expected to retain a tightening bias. Any pause or change of direction will depend on inflation. We expect liquidity to remain tight, and, despite advance tax flows, the CRR hike, along with RBI intervention in forex markets, should remove excess liquidity from the system. The increased differential between repo/reverse repo rate is in line with the central bank’s stated policy of maintaining a wider band in uncertain times. Any unexpected increase in government’s borrowing programme leading to higher bond issuances will impact the demand-supply scenario. The average duration of our portfolios continues to be on the lower side, and we are focusing on accrual products. Investors should look to focus on funds such as shortterm floating rate funds, fixed maturity plans, and ultra short bond funds.

Courtesy: Franklin Templeton

 

© blogger templates 3 column | Make Money Online